Mantle Cell Lymphoma
Video
VIDEO: First multicenter trial of CAR T cells shows response in DLBCL
SAN DIEGO - Aggressive, refractory non-Hodgkin lymphomas responded to anti-CD19 chimeric antigen receptor T cells in ZUMA-1, the first...
Conference Coverage
Chemo-free induction regimen shines in MCL
SAN DIEGO – A chemotherapy-free induction regimen of ibrutinib and rituximab was well tolerated and achieved an overall response rate of 100%...
Conference Coverage
Rituximab vanquished MRD in mantle cell lymphoma
SAN DIEGO – Rituximab can at least temporarily vanquish minimal residual disease in mantle cell lymphoma patients who relapse after induction...
Conference Coverage
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
SAN DIEGO – For patients with indolent non-Hodgkin lymphoma, adding rituximab to a standard-combination chemotherapy regimen resulted in...
Conference Coverage
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
SAN DIEGO – Obinutuzumab, a second-generation anti-CD20 antibody touted as the heir apparent to rituximab, offered a PFS edge over rituximab when...
News
Ibrutinib bodes well for relapsed mantle-cell lymphoma
Key clinical point: Ibrutinib significantly improved progression-free survival, compared with temsirolimus in patients with relapsed or refractory...
News
Ki-67 bests cytology, growth pattern as prognostic factor for MCL
Key clinical point: The Ki-67 index was superior to cytology and growth pattern as a prognostic factor in mantle-cell lymphoma (MCL).
News
Lenalidomide plus rituximab achieves 87% response rate
Key clinical point: First-line combination biologic therapy with lenalidomide plus rituximab produced an 87% overall response rate in stage 3 or 4...
Conference Coverage
RBAC500 safe, effective for elderly patients with mantle cell lymphoma
Key clinical point: Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed a regimen of rituximab, bendamustine, and cytarabine to be...
News
Bendamustine regimen may be induction-therapy option in mantle cell lymphoma
Key clinical point: Rituximab plus bendamustine may prove to be an option for induction therapy prior to autologous stem cell transplant in...